|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triple-negative breast cancer (ie, those with negative estrogen receptor, progesterone receptor, and HER-2/neu status) was diagnosed in 57.1% of the BRCA1-positive patients, 23.3% of the BRCA2-positive patients, and 13.8% of the BRCA-negative patients.
|
18779615 |
2008 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the intriguing characteristics of triple-negative breast cancer is its association with cancers arising in BRCA1 mutation carriers, in young women and in African-American women.
|
19008097 |
2008 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, BRCA1 testing in triple-negative breast cancer patients resistant to docetaxel-based treatment may help to identify families with germinal mutations without a history of hereditary breast cancer.
|
18591931 |
2008 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
|
18197009 |
2008 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Women with early-onset triple-negative breast cancer are candidates for genetic testing for BRCA1, even in the absence of a family history of breast or ovarian cancer.
|
19298662 |
2009 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Poly (ADP-ribose) polymerase inhibitors, angiogenesis inhibitors, EGFR-targeted agents, and src kinase and mTOR inhibitors are among the therapeutic agents being actively investigated in clinical trials in patients with TNBC and/or BRCA1-associated tumors.
|
20877296 |
2010 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because sporadic triple-negative breast cancer (TNBC) and BRCA1-associated breast cancer share features suggesting common pathogenesis, we conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to identify predictors of response.
|
20100965 |
2010 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A better understanding of the shared biology of BRCA1-associated breast cancer and sporadic TNBC holds much promise for changing the outlook for women with this aggressive disease.
|
21421115 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The development of poly-(ADP)ribose polymerase inhibitors for BRCA1-mutation carriers with TNBC has led the ongoing efforts to translate fundamental biological insights into improved therapies for a difficult-to-treat breast cancer subgroup.
|
21986848 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the incidence of germline and somatic BRCA1/2 mutations in unselected patients with triple-negative breast cancer (TNBC) and determine the prognostic significance of carrying a mutation.
|
21233401 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
|
21264845 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over the last few years, excitement over this class of agents has escalated due to reported activity as single agent in BRCA1- or BRCA2-associated ovarian or breast cancers, and in combination with chemotherapy in triple negative breast cancer.
|
21718592 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression patterns of BRCA1, pRb, p16 and PTEN were highly correlated, and define a subgroup of TNBCs characterized by BRCA1 aberrations, high Ki-67 (≥ 40%) and favorable disease outcome.
|
21593597 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
|
22010008 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triple-negative breast cancer (TNBC) is characterized by lack of hormone receptors and HER-2 and shares many features with BRCA1-associated cancer.
|
21482494 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, mouse models of a 'triple-negative' breast cancer (utilizing conditional knockout of BRCA1 and p53 in the breast), of an endometrioid ovarian cancer (based on oncogenic kras and loss of function of pten), and of anatomic and functional consequences of BRCA1 mutations in granulosa cells, have led to further inquiry into the pathogenesis and therapeutic consequences of genetic alterations.
|
21285156 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TNBC also includes the normal-like subtype, and not all patients with TNBC harbor BRCA1 mutations.
|
21161370 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Founder mutations were detected in 48 samples (10.6%) including 25/64 TNBC (39.1%; 19 BRCA1, 6 BRCA2).
|
21394499 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified.
|
19813073 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PARP inhibitors are being investigated as a monotherapy for the treatment of patients with BRCA 1/2 mutations; in the treatment of triple-negative breast cancer, because of its molecular similarities to BRCA1-mutated malignancies; and as a strategy to potentiate the DNA-damaging effects of chemotherapy and radiation.
|
22106552 |
2011 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we screened a group of TNBC patients (n = 30) of white European descent for mutations in BRCA2 as well as in BRCA1.
|
22666503 |
2012 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that elevated CA IX protein in TNBC is associated with a BRCA1 mutant signature and loss of BRCA1 function.
|
22976806 |
2012 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study assessed BRCA1 and BRCA2 mutation prevalence in an unselected cohort of patients with triple-negative breast cancer (BC).
|
22614657 |
2012 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This implies that TNBC cells may harbor a dysfunctional BRCA1 repair pathway.
|
23203101 |
2012 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that among women diagnosed with breast cancer aged 36 to 50 years but with no family history of breast or ovarian cancer, the prevalence of BRCA1 and BRCA2 mutations was similar in TNBC (8.5%) and non-TNBC patients (6.7%).
|
23116406 |
2012 |